Skip to main content
Clinical Trials/NCT04467879
NCT04467879
Terminated
Not Applicable

A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients

Zona Health, Inc5 sites in 1 country146 target enrollmentJune 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypertension, Systolic
Sponsor
Zona Health, Inc
Enrollment
146
Locations
5
Primary Endpoint
Change from Baseline in Systolic Blood Pressure to Day 70 ± 2 Days
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

This is a double-blind, sham-controlled clinical trial assessing the effectiveness of personalized isometric handgrip device therapy. Approximately 230 patients who present with a Systolic Blood Pressure reading of ≤ 149mmHg and who have not taken any antihypertensive medication for more than 30 days will be enrolled.

Detailed Description

This study is designed to examine the effectiveness of individualized isometric handgrip device therapy in prehypertension or hypertension patient subjects who are not at target BP and who are naive to anti-hypertensive medication for at least 30 days before screening. The investigational plan examines changes in blood pressure (BP) in up to 230 patient subjects who are randomized to either the "active" (i.e., the Zona Plus device proposed for marketing), or to a "sham" device (which is intentionally calibrated for a "weaker grip").

Registry
clinicaltrials.gov
Start Date
June 1, 2020
End Date
September 14, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change from Baseline in Systolic Blood Pressure to Day 70 ± 2 Days

Time Frame: Change from Baseline to Day 70 ±2 Days

Comparative assessment in the change from Baseline in seated cuff Systolic Blood Pressure after ten(10) weeks of treatment between patients treated with the Zona Plus nominal device ("stronger grip") and patients treated with the Placebo control device ("weaker grip"). A reduction in Systolic Blood ≥ 5 Preassure after 10 weeks of treatment is considered to be a better outcome.

Secondary Outcomes

  • Comparison of Heart Rate between Zona Plus nominal device and Placebo controlled device(Change from Baseline to Day 160 ± 4 Days)
  • Change from Baseline in Diastolic Blood Pressure to Day 70 ± 2 Days(Change from Baseline to Day 70 ±2 Days)
  • Percentage change from Baseline in Systolic Blood Pressure reduction at Day 70 ± 2 Days(Change from Baseline to Day 70 ± 2 Days)
  • Percentage change from Baseline in Diastolic Blood Pressure reduction at Day 70 ± 2 Days(Change from Baseline to Day 70 ± 2 Days)
  • Percentage change from Baseline in Systolic Blood Pressure reduction at Day 160 ± 4 Days(Change from Baseline to Day 160 ± 4 Days)
  • Percentage change in Diastolic Blood Pressure reduction at Day 160 ± 4 Days(Change from Baseline to Day 160 ± 4 Days)

Study Sites (5)

Loading locations...

Similar Trials